Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world data

Area of Science:

• Hematology
• Oncology
• Immunotherapy

Background:

• Glofitamab, a CD3xCD20 bispecific antibody, shows promise in clinical trials for B-cell lymphomas.
• Real-world data for glofitamab in diffuse large B-cell lymphoma (DLBCL) patients, especially those with extensive prior treatment, is limited.
• Understanding outcomes in a broader, unselected patient population is crucial for treatment guidance.

Purpose of the Study:

• To assess the real-world effectiveness and safety of glofitamab in patients with relapsed/refractory (R/R) DLBCL.
• To evaluate treatment outcomes, including response rates, survival, and toxicity, in a Turkish patient cohort.
• To provide insights into the use of glofitamab in a heavily pretreated, diverse patient population.

Main Methods:

• Retrospective analysis of 43 R/R DLBCL patients treated with glofitamab via compassionate use across 20 centers in Turkey.
• Data collection included patient demographics, prior treatments, treatment response, survival, and adverse events.
• Median follow-up was 5.7 months.

Main Results:

• Overall response rate (complete + partial) was 37% in efficacy-evaluable patients.
• Median progression-free survival (PFS) was 3.3 months and median overall survival (OS) was 8.8 months.
• Hematological toxicity was the most frequent adverse event; treatment-related mortality occurred in 3 patients (cytokine release syndrome, febrile neutropenia).

Conclusions:

• Glofitamab demonstrated a median OS of approximately 9 months in a heavily pretreated R/R DLBCL population, suggesting potential benefit.
• Real-world effectiveness is encouraging, but careful monitoring for toxicities, particularly hematological events and cytokine release syndrome, is essential.
• This study represents the largest real-world evaluation of glofitamab in R/R DLBCL, highlighting the need for continued safety surveillance.